Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer

NCT01307631 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01307631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01307631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
September 18, 2015
Enrollment
37 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, recurrent uterine corpus carcinoma